Alvotech Faces Class Action for Misleading Business Information
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Globenewswire
- Legal Investigation Initiated: Rosen Law Firm is investigating Alvotech for potentially issuing misleading business information, and investors who purchased Alvotech securities may be entitled to compensation without any out-of-pocket fees.
- Significant Stock Decline: Following the FDA's complete response letter regarding its Biologics License Application on November 2, 2025, Alvotech's stock plummeted 34% on November 3 and nearly 4% on November 4, indicating strong market concerns about its future prospects.
- FDA Feedback Issues: The FDA's response letter highlighted deficiencies found during the inspection of Alvotech's Reykjavik manufacturing facility that must be resolved before approval of the AVT05 application, severely impacting investor confidence.
- Class Action Preparation: Rosen Law Firm is preparing a class action to recover losses for investors, reflecting the firm's serious attention to Alvotech's legal troubles and its commitment to providing relief for affected investors through legal channels.
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALVO is 10.67 USD with a low forecast of 8.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 5.050
Low
8.00
Averages
10.67
High
14.00
Current: 5.050
Low
8.00
Averages
10.67
High
14.00
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
